Terms: = Breast cancer AND ARNT, HIF1BETA, 405, ENSG00000143437, P27540, HIF-1beta, HIF1B, TANGO AND Treatment
150 results:
1. Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
2. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer.
Lin CJ; Jin X; Ma D; Chen C; Ou-Yang Y; Pei YC; Zhou CZ; Qu FL; Wang YJ; Liu CL; Fan L; Hu X; Shao ZM; Jiang YZ
Cancer Cell; 2024 Apr; 42(4):701-719.e12. PubMed ID: 38593782
[TBL] [Abstract] [Full Text] [Related]
3. The Garlic Compound, Diallyl Trisulfide, Attenuates Benzo[a]Pyrene-Induced Precancerous Effect through Its Antioxidant Effect, AhR Inhibition, and Increased DNA Repair in Human breast Epithelial Cells.
Ferguson DT; Taka E; Messeha S; Flores-Rozas H; Reed SL; Redmond BV; Soliman KFA; Kanga KJW; Darling-Reed SF
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38276538
[TBL] [Abstract] [Full Text] [Related]
4. The Anticancer Effects of the Garlic Organosulfide Diallyl Trisulfide through the Attenuation of B[a]P-Induced Oxidative Stress, AhR Expression, and DNA Damage in Human Premalignant breast Epithelial (MCF-10AT1) Cells.
Ferguson DT; Taka E; Tilghman SL; Womble T; Redmond BV; Gedeon S; Flores-Rozas H; Reed SL; Soliman KFA; Kanga KJW; Darling-Reed SF
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255999
[TBL] [Abstract] [Full Text] [Related]
5. Overall Survival With Palbociclib Plus Letrozole in Advanced breast cancer.
Slamon DJ; Diéras V; Rugo HS; Harbeck N; Im SA; Gelmon KA; Lipatov ON; Walshe JM; Martin M; Chavez-MacGregor M; Bananis E; Gauthier E; Lu DR; Kim S; Finn RS
J Clin Oncol; 2024 Mar; 42(9):994-1000. PubMed ID: 38252901
[No Abstract] [Full Text] [Related]
6. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of the breast cancer Journey in Namibia.
Boucheron P; Zietsman A; Pontac J; Hansen R; Anderson BO; Togawa K; Macharia PM; Foerster M; Schüz J; Dos-Santos-Silva I; McCormack V
JAMA Netw Open; 2023 Nov; 6(11):e2341402. PubMed ID: 37921764
[TBL] [Abstract] [Full Text] [Related]
8. PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China.
Liu X; Liu Z; Li C; Song X; Wang X; Li S; Yu Z
World J Surg Oncol; 2023 Sep; 21(1):296. PubMed ID: 37723497
[TBL] [Abstract] [Full Text] [Related]
9. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data.
Lantis K; Schnell P; Bland CR; Wilder J; Hock K; Vargo C; Glover NA; Hackney ME; Lustberg MB; Worthen-Chaudhari L
Trials; 2023 Sep; 24(1):564. PubMed ID: 37658464
[TBL] [Abstract] [Full Text] [Related]
10. NEK8 regulates colorectal cancer progression via phosphorylating MYC.
Cao B; Zhang K; Pan C; Dong Y; Lu F
Cell Commun Signal; 2023 Aug; 21(1):209. PubMed ID: 37596667
[TBL] [Abstract] [Full Text] [Related]
11. Surgical Management of Metastatic Pathologic Subtrochanteric Fractures: treatment Modalities and Associated Outcomes.
Inchaustegui ML; Ruiz K; Gonzalez MR; Pretell-Mazzini J
JBJS Rev; 2023 May; 11(5):. PubMed ID: 37141383
[TBL] [Abstract] [Full Text] [Related]
12. National and subnational burden of female and male breast cancer and risk factors in Iran from 1990 to 2019: results from the Global Burden of Disease study 2019.
Aryannejad A; Saeedi Moghaddam S; Mashinchi B; Tabary M; Rezaei N; Shahin S; Rezaei N; ; Naghavi M; Larijani B; Farzadfar F
Breast Cancer Res; 2023 Apr; 25(1):47. PubMed ID: 37101247
[TBL] [Abstract] [Full Text] [Related]
13. "Time" for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment.
Miro C; Docimo A; Barrea L; Verde L; Cernea S; Sojat AS; Marina LV; Docimo G; Colao A; Dentice M; Muscogiuri G
Semin Cancer Biol; 2023 Jun; 91():99-109. PubMed ID: 36893964
[TBL] [Abstract] [Full Text] [Related]
14. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Tolaney SM; Tarantino P; Graham N; Tayob N; Parè L; Villacampa G; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Barroso-Sousa R; Villagrasa P; DeMeo M; DiLullo M; Zanudo JGT; Weiss J; Wagle N; Partridge AH; Waks AG; Hudis CA; Krop IE; Burstein HJ; Prat A; Winer EP
Lancet Oncol; 2023 Mar; 24(3):273-285. PubMed ID: 36858723
[TBL] [Abstract] [Full Text] [Related]
15. Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases.
Yuan S; Wang L; Zhang H; Xu F; Zhou X; Yu L; Sun J; Chen J; Ying H; Xu X; Yu Y; Spiliopoulou A; Shen X; Wilson J; Gill D; Theodoratou E; Larsson SC; Li X
EBioMedicine; 2023 Mar; 89():104488. PubMed ID: 36842216
[TBL] [Abstract] [Full Text] [Related]
16. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
17. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH; Sadri M; Najafi A; Rahimi A; Baghernejadan Z; Khorramdelazad H; Falak R
Front Immunol; 2022; 13():1018962. PubMed ID: 36389779
[TBL] [Abstract] [Full Text] [Related]
18. Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Berrios K; Burum A; Jeong E; Zhong L
J Manag Care Spec Pharm; 2022 Nov; 28(11):1282-1291. PubMed ID: 36282933
[No Abstract] [Full Text] [Related]
19. Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor-Positive breast cancer.
Hu X; Kaplan CM; Martin MY; Walker MS; Stepanski E; Schwartzberg LS; Vidal GA; Graetz I
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):167-174. PubMed ID: 36166516
[TBL] [Abstract] [Full Text] [Related]
20. 2022 Practice Recommendation Updates From the World Consensus Conference on BIA-ALCL.
Santanelli di Pompeo F; Clemens MW; Atlan M; Botti G; Cordeiro PG; De Jong D; Di Napoli A; Hammond D; Haymaker CL; Horwitz SM; Hunt K; Lennox P; Mallucci P; Miranda RN; Munhoz AM; Swanson E; Turner SD; Firmani G; Sorotos M
Aesthet Surg J; 2022 Oct; 42(11):1262-1278. PubMed ID: 35639805
[TBL] [Abstract] [Full Text] [Related]
[Next]
